IUB288

IUB288 (0.3-10 nmol/kg/day; daily; up to 18 days) produces potent body weight and fat mass loss, reduces plasma cholesterol, increases blood glucose, and suppresses hepatic HMGCR expression in diet-induced obese male C57Bl/6J mice^[1].
IUB288 (10 nmol/kg; i.p.; single dose) increases blood glucose in chow-fed mice and stimulates transient FGF21 secretion in obese mice, while IUB288 (10 nmol/kg/day; daily; 16 days) chronic treatment increases food intake and plasma triglycerides without altering body weight in chow-fed mice^[1].
IUB288 (10 nmol/kg/day; daily; 7 days) reduces body weight, increases core body temperature, and enhances insulin sensitivity in leptin receptor-deficient db/db mice without altering blood glucose or food intake^[1].
IUB288 (10 nmol/kg/day; daily; 20 days) prevents diet-induced weight gain, increases EE, and reduces plasma cholesterol in WT mice, but these effects are ablated in FGF21-deficient mice, demonstrating FGF21 is required for most long-term metabolic actions of IUB288^[1].
IUB288 (10 nmol/kg/day; daily; 18 days) increases hepatic FGF21 expression and circulating FGF21 levels in diet-induced obese mice^[1].
IUB288 (10 nmol/kg; s.c.; daily) reduces body weight and suppresses food intake in diet-induced obese C57Bl/6J mice, and its associated glucose intolerance is rescued by co-treatment with bile acid sequestration resins, which also enhance its anti-obesity effect^[2].